Table 3 Subjects with PD, DLB and ILBD exhibit specific tau and Aβ deposits in pancreatic β cells
Groups | pSer202-Thr205 | pThr212-Ser214 | pThr231 | pThr181 | pSer262 Tau | pSer 422 Tau | Oligomeric Tau | Asp421-cleaved Tau | Tau | Tau | Aβ (4G8) |
|---|---|---|---|---|---|---|---|---|---|---|---|
Tau | Tau | Tau | Tau | Alz50 | MC1 | ||||||
Incidental Lewy body disease | 7/8 (88%) | 6/8 (75%) | 1/8 (13%) | 8/8 (100%) | 8/8 (100%) | 5/8 (63%) | 10/10 (100%) | 6/8 (75%) | 6/8 (75%) | 2/8 (25%) | 2/8 (25%) |
Parkinson's disease | 10/10 (100%) | 9/10 (90%) | 4/10 (40%) | 10/10 (100%) | 10/10 (100%) | 8/10 (80%) | 8/10 (80%) | 8/10 (80%) | 10/10 (100%) | 4/10 (40%) | 3/10 (30%) |
Dementia with Lewy bodies | 12/12 (100%) | 12/12 (100%) | 7/12 (58%) | 12/12 (100%) | 12/12 (100%) | 10/12 (83%) | 9/12 (83%) | 10/12 (83%) | 12/12 (100%) | 5/12 (42%) | 4/12 (33%) |
Normal neuropathological examination* | 15/29 (52%) | 14/29 (48%) | 7/29 (24%) | 24/29 (83%) | 26/29 (90%) | 12/29 (41%) | 7/29 (24%) | 6/29 (21%) | 23/29 (79%) | 4/29 (14%) | 3/29 (10%) |
Normal neuropathological examination with T2DM* | 13/19 (68%) | 19/19 (53%) | 7/19 (37%) | 17/19 (89%) | 19/19 (100%) | 8/19 (42%) | 10/19 (53%) | 6/19 (32%) | 15/19 (79%) | 6/19 (32%) | 3/19 (16%) |
Alzheimer disease with a low neuropathologic change* | 22/28 (79%) | 24/28 (86%) | 14/28 (50%) | 21/28 (75%) | 28/28 (100%) | 17/28 (61%) | 21/28 (75%) | 11/28 (39%) | 24/28 (86%) | 9/28 (32%) | 10/28 (36%) |
Alzheimer disease with an intermediate neuropathologic change* | 22/26 (85) | 24/26 (92%) | 14/26 (54%) | 23/26 (88%) | 26/26 (100%) | 18/26 (69%) | 22/26 (85%) | 12/26 (46%) | 25/26 (96%) | 12/26 (46%) | 10/26 (38%) |
Alzheimer disease with a high neuropathologic change* | 8/8 (100%) | 8/8 (100%) | 5/8 (63%) | 8/8 (100%) | 8/8 (100%) | 4/8 (50%) | 7/8 (88%) | 7/8 (88%) | 8/8 (100%) | 7/8 (88%) | 4/8 (50%) |